



Malmö 30 June 2021

PRESS RELEASE

Aptahem receives Notice of Allowance from the US Patent Office for the protection of patent family 2

Aptahem AB (publ) announces today that the company has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the US patent application 16/652,926 entitled *A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties*. The application covers the therapeutic protection of the company's aptamer Aptahem-1 which is being developed as treatment for disease syndromes caused by inflammation, coagulation and/or organ failure.

This application is part of the patent family 2 with Aptahem's CSO Dr Luiza Jedlina as the inventor. Aptahem has now received a Notice of Allowance for this application. The company has informed the authority that the fee will be paid to receive the approval and to have an Issue Notification and the official patent number for the approved patent. When the patent will be officially approved it will be valid until 2037.

CEO Mikael Lindstam comments:

"I am very pleased to receive the information about the intention in the USA to approve our second patent family which protects the therapeutic areas for Aptahem-1. This means a significant increase of the value of Aptahem's portfolio, not least in our continued partnering discussions. This is a strong confirmation on all the hard work to drive Aptahem-1 forward to the patients in need, and the whole team sees this information as a reward for all our efforts."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

This contains such information that Aptahem AB is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the above contact person for publication on 30 June 2021.

About Sepsis

Sepsis is today considered a world health problem and affects 49 million people worldwide each year, of which 11 million die. In Europe alone, over 1 million people are estimated to be affected by sepsis on a yearly basis*. There is currently no specific treatment for sepsis, but instead the underlying symptoms are treated with antibiotics, fluids and oxygen.

* Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL, Naghavi M. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. *Lancet*. 2020 Jan 18;395(10219):200-211. doi: 10.1016/S0140-6736(19)32989-7. PMID: 31954465; PMCID: PMC6970225.

About Aptahem

Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Aptahem-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.